Saracatinib
Hormone-Resistant Prostate Carcinoma
Explore 3 assets in Hormone-Resistant Prostate Carcinoma →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01267266CT.gov Saracatinib in Treating Patients With Prostate Cancer | — | Terminated | — | — | — |
NCT00513071CT.gov AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hormone-Resistant Prostate Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Saracatinib (this asset) | National Cancer Institute (NCI) | P2 | B · 57 |
| Abiraterone | Alliance for Clinical Trials in Oncology | P3 | BB |
| Prednisone | University of California, Davis | P3 | BB |
| Docetaxel | Seattle Institute for Biomedical and Clinical Research | P3 | BB |
| Enzalutamide | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | P3 | BB |
| Bicalutamide | Mayo Clinic | P2 | B |
| Pembrolizumab | University of Wisconsin, Madison | P2 | B |
| Sipuleucel-T | Roswell Park Cancer Institute | P2 | B |
| Ipilimumab | OHSU Knight Cancer Institute | P2 | B |
+41 more in the Hormone-Resistant Prostate Carcinoma cohort
Other indications for Saracatinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Cancer | — | P2 | B · 62 |
| Alzheimer Disease | — | P2 | B · 58 |
| Metastatic Neoplasm | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Saracatinib in Hormone-Resistant Prostate Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/saracatinib-hormone-resistant-prostate-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →